STOCK TITAN

NUTRA PHARMA CORP - $NPHC STOCK NEWS

Welcome to our dedicated page for NUTRA PHARMA news (Ticker: $NPHC), a resource for investors and traders seeking the latest updates and insights on NUTRA PHARMA stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NUTRA PHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NUTRA PHARMA's position in the market.

Rhea-AI Summary
Nutra Pharma Corp. settles with SEC, CEO resigns, and new leadership appointed with exciting growth plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.55%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.47%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.49%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
NUTRA PHARMA CORP

OTC:NPHC

NPHC Rankings

NPHC Stock Data

759.68k
7.51B
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Plantation

About NPHC

nutra pharma corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. the company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. currently, nutra pharma offers several drug products for sale for the treatment of pain: nyloxin, the first over-the-counter (otc) pain reliever clinically proven to treat moderate to severe (stage 2) chronic pain, and nyloxin extra strength, the only non-narcotic and non-addictive treatment for severe (stage 3) pain. see: www.nyloxin.com nutra pharma also offers pet pain-away: a product aimed at treating moderate to severe chronic pain in companion animals. pet pain-away is specifically indicated to treat pain from hip dysplasia, arthrit